Navigation Links
Rib-X Pharmaceuticals, Inc. Appoints Tom Kassberg Chief Business Officer
Date:9/4/2009

NEW HAVEN, Conn., Sept. 4 /PRNewswire/ -- Rib-X Pharmaceuticals, Inc., a development-stage company focused on the discovery, development and commercialization of novel antibiotics for the treatment of acute care antibiotic-resistant infections, announced today that Thomas R. Kassberg has joined the company as Chief Business Officer. In his new role, Mr. Kassberg will lead the company's business development activities.

Mr. Kassberg, age 49, joins Rib-X from Proteolix, Inc., where he served as Executive Vice President of Corporate Development, overseeing business development, corporate strategic planning and legal affairs. Prior to Proteolix, Mr. Kassberg had over a decade of experience in leadership roles in business development in the biotechnology industry, holding positions at InterMune, Inc., Plexxikon, Inc. (a company he co-founded), and SUGEN, Inc.

Mr. Kassberg began his career at Bristol-Myers Squibb where he held a variety of positions in finance, product and market analysis, and sales. Mr. Kassberg received his M.B.A. from the Kellogg Graduate School of Management at Northwestern University and his B.A. from Gustavus Adolphus College in Minnesota.

"Tom joins Rib-X at a particularly important time in our growth, as we explore potential partnership opportunities for our lead antibiotic compounds, delafloxacin and radezolid, which have successfully completed multiple Phase 2 clinical trials," said Susan Froshauer, PhD, President and Chief Executive Officer of Rib-X Pharmaceuticals. "His business development experience and background are an ideal fit for what we need at this stage in our maturation."

About Rib-X Pharmaceuticals, Inc.

Rib-X Pharmaceuticals, Inc. is a product-driven small molecule drug discovery and development company focused on the structure-based design of new classes of antibiotics. The Company's underlying drug discovery engine capitalizes on its proprietary high-resolution crystal structure of the ribosome, which performs an essential role in protein synthesis. Many known, commercially valuable antibiotics exert their effects by binding to the bacterial ribosome. The Company's integrated research strategy, which combines state-of-the-art, proprietary computational analysis, X-ray crystallography, medicinal chemistry, microbiology and biochemistry, allows it to rapidly synthesize new agents designed to avoid typical antibiotic resistance mechanisms. Rib-X's iterative intelligent engine has yielded several distinctive new antibiotics that can be used for the treatment of either community- or hospital-acquired infections. In addition to Rx-04, Rib-X has successfully completed Phase 2 trials with delafloxacin (RX-3341), a broad spectrum fluoroquinolone with potent activity against quinolone resistant Gram-positive bacteria including MRSA. Radezolid (RX-1741), an oxazolidinone that was discovered at Rib-X, as an oral/IV agent for treatment of serious Gram-positive infections has completed two Phase 2 trials and the Rx-02 discovery program which is focused on developing an IV/oral macrolide active against methicillin-resistant S. aureus, multidrug-resistant Streptococcus pneumoniae and S. pyogenes. Both delafloxacin and radezolid are currently in late stage clinical trials.

For more information on the Rib-X mission and the pipeline, please visit the Company website at www.rib-x.com.


'/>"/>
SOURCE Rib-X Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Rib-X Granted Key Antibiotic Patent in China
2. Rib-X Pharmaceuticals, Inc. to Present at the Rodman & Renshaw 10th Annual Healthcare Conference
3. Rib-X CEO Susan Froshauer, PhD, Honored by The Connecticut Womens Hall of Fame
4. EPIX Pharmaceuticals, Inc. Announces the P2Y2 Gastrointestinal Early Development Candidate Program Will Be Part of the Intellectual Property Offered For Sale at the September 30, 2009 Auction
5. Keryx Biopharmaceuticals, Inc. To Present at the Rodman & Renshaw Annual Global Investment Conference and To Hold Investor/Analyst Day
6. AUDIO from Medialink, Boehringer Ingelheim Pharmaceuticals, Inc. & Pfizer Inc.: Coping with Chronic Obstructive Pulmonary Disease (COPD)
7. The Rossbacher Law Firm, Hagens Berman Sobol Shapiro LLP, Wilentz Goldman & Spitzer, P.A., Reed Smith LLP and Thompson Hine LLP, Announce the Proposed Settlement of a Class Action Lawsuit Concerning Estratest and Solvay Pharmaceuticals, Inc.
8. Epix Pharmaceuticals, Inc. Announces PRX-07034 Therapeutics - CNS Phase 2 Will be Part of the Intellectual Property Offered for Sale at the September 30, 2009 Auction
9. MAP Pharmaceuticals, Inc. Announces Pricing of Public Offering of Common Stock
10. DUSA Pharmaceuticals, Inc.(R) Announces Second Quarter Financial Results and Corporate Highlights Conference Call
11. EPIX Pharmaceuticals, Inc. Announces August 25, 2009 for the Auction Sale of Equipment and September 30, 2009 for the Auction Sale of the Intellectual Property
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/12/2016)... ... February 12, 2016 , ... ... Pittsburgh metro area, celebrates the beginning of the latest charity campaign in their ... skills through art. Donations to this worthy cause are currently being accepted at: ...
(Date:2/12/2016)... (PRWEB) , ... February 12, 2016 , ... ... “Revolutionizing Cancer Care.” , The print component of “Revolutionizing Cancer Care” ... Pittsburgh/Cleveland, New York, Washington DC/Baltimore, and Seattle, with a circulation of approximately 250,000 ...
(Date:2/12/2016)... ... , ... A lot has been reported about the fitness routines of United ... and wellness resources most Americans could ever dream of having at their disposal. However, ... frenetic as the U.S. President. , In honor of President’s Day on Feb. ...
(Date:2/12/2016)... ... February 12, 2016 , ... Basketball is a game for everyone, not just ... PoppersTM series, sign language translation is featured in the top right of the screen. ... PoppersTM lessons has a sign language translator to teach kids the game and how ...
(Date:2/11/2016)... ... February 11, 2016 , ... “ HEALING MIND : Five Steps ... Mind” (published by Balboa Press) teaches readers how to become their own therapist. Providing ... author Janice McDermott, M.Ed., LCSW, offers an understanding of how to heal one’s inner ...
Breaking Medicine News(10 mins):
(Date:2/12/2016)... VIEJO, Calif. , Feb. 12, 2016  Sequent ... enrollment in a study to evaluate the safety and ... for the treatment of ruptured intracranial aneurysms.  Prof ... University Hospital, in Paris, France ... first patient. France and ...
(Date:2/12/2016)... INDIANAPOLIS , Feb. 12, 2016  Eli Lilly and ... High Court decided the Alimta® (pemetrexed disodium) vitamin regimen patent ... in the UK, France , ... instructions to dilute the product only with dextrose solution.  ... of 2015, the UK Court of Appeal held that Lilly,s ...
(Date:2/12/2016)... , 12 februari 2016 ... een toonaangevende leverancier van productie en ontwikkeling ... industrieën, kondigt vandaag een uitbreiding aan van ... haar locatie in Charleston, SC ... geleid tot meerdere recente investeringen. ...
Breaking Medicine Technology: